Private equity gets serious about drug development
Venture capital has the brains, private equity has the books – can they make lots of money?
The trigger for a Seagen buyout
Seagen is vulnerable to takeover, but whether a deal happens – and at what price – depends on at least one catalyst.
The lowdown on high blood pressure
After Idorsia’s tease in resistant hypertension, data will soon emerge on other advanced assets, including long-acting RNA-based approaches.
The next generation of diabetes technology
New devices are coming, but the real advances will involve combinations.
Late-stage pain pipeline refuses to swell
Setbacks from Eliem, Ampio and Acadia thin an already sparse pain pipeline, which remains lacking in serious interest from big developers.
Problems Facing The Current Generation Of Genetic Medicines
A new report from Evaluate Vantage looks at new approaches aiming to solve problems facing the current generation of genetic medicines.
Amylyx faces an uphill battle
Briefing documents show why the FDA should await more data on the ALS project, but will it bow to patient pressure?
The year the regulators meet the microbiome
With Ferring filed and Seres preparing to do so, regulators' views on microbiome approaches to C difficile will soon be heard.
